Dose-dependent augmentation effect of bromocriptine in a case with refractory depression

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Refractory depression poses a significant clinical challenge, often requiring novel therapeutic strategies.
• Standard treatments, including electroconvulsive therapy (ECT) and augmentation with lithium or triiodothyronine, were ineffective in this patient.
• Investigating alternative augmentation agents is crucial for managing treatment-resistant depression.

Observation:

• A patient with refractory depression experienced symptom improvement with the addition of bromocriptine (2.5-5 mg/day) to imipramine.
• Increasing the bromocriptine dose to 15 mg/day led to clinical deterioration, with symptoms returning to baseline.
• Reducing the bromocriptine dose back to 5 mg/day resulted in renewed improvement of depressive symptoms.

Findings:

• Bromocriptine demonstrates a clear augmentation effect in treating refractory depression when combined with imipramine.
• The therapeutic efficacy of bromocriptine in this context is dose-dependent.
• An optimal dose range for bromocriptine augmentation appears to exist, beyond which efficacy diminishes or adverse effects emerge.

Implications:

• This case highlights the potential of bromocriptine as an adjunctive therapy for specific patient populations with treatment-resistant depression.
• The observed dose-dependency suggests the need for careful dose titration and monitoring when using bromocriptine for depression.
• Further research is warranted to elucidate the mechanisms underlying bromocriptine's dose-dependent effects and to establish its broader clinical utility in psychiatry.